Advertisement
MGNX vs VYGR
Which Stock Would AI Choose? MacroGenics (MGNX) vs. Voyager Therapeutics (VYGR) Stock Comparison
Key Takeaways
- MacroGenics (MGNX) has posted sharply positive relative performance in recent months, supported by non-dilutive capital raises and a strengthened balance sheet.
- Voyager Therapeutics (VYGR) has faced meaningful downward price pressure in recent weeks despite a large cash balance and a strong "Buy" analyst consensus.
- The two companies operate in different segments of biotechnology: MGNX focuses on antibody-based oncology, while VYGR develops gene therapies for neurological diseases.
- Both stocks carry clinical-stage risk, but MGNX currently shows more consistent upward trend momentum, whereas VYGR is in a clearer downtrend.
- For additional detail on each name's developments and daily activity, explore the MGNX Major News and MGNX Today's Price Move pages, as well as the VYGR Major News and VYGR Today's Price Move pages.
- To see how automated systems are positioning across this and other pairs, explore the Trending AI Robots section.
Introduction
Investors screening clinical-stage biotechnology names frequently encounter MGNX (MacroGenics, Inc.) and VYGR (Voyager Therapeutics, Inc.) as small-cap opportunities with distinct scientific platforms. MacroGenics develops antibody-based cancer therapeutics, while Voyager advances gene therapy approaches for serious neurological conditions. A head-to-head stock comparison is useful for traders weighing momentum against valuation and for longer-horizon investors assessing pipeline quality, cash runway, and partnership economics. Because both companies remain pre-profit and depend on clinical milestones, their share prices are especially sensitive to news flow, making their relative performance and market positioning worth tracking closely in the current environment.
MGNX Overview and Recent Performance
MacroGenics, headquartered in Rockville, Maryland, is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including bispecific DART molecules and antibody-drug conjugates (ADCs), which are engineered antibodies that deliver a toxic payload directly to cancer cells. In recent weeks, MGNX has been among the more constructive names in small-cap biotech, with the stock advancing substantially over the past year and holding a notably higher market positioning than its 52-week lows.
Several developments have supported sentiment. The company strengthened its balance sheet through a royalty monetization agreement tied to ZYNYZ (retifanlimab) with Sagard Healthcare Partners and an agreement to sell its manufacturing operations to Bora Pharmaceuticals, transactions that together could generate more than $200 million in non-dilutive capital and extend its cash runway into 2028. At the same time, MGNX has progressed its ADC pipeline, including MGC026, while navigating an FDA (U.S. Food and Drug Administration) partial clinical hold on its LINNET study of lorigerlimab that was later lifted. Analysts have responded with a consensus "Buy" rating and an average price target well above recent trading levels.
VYGR Overview and Recent Performance
Voyager Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on gene therapies for neurological diseases, built around its TRACER platform for delivering therapies across the blood-brain barrier. Its pipeline includes the anti-tau antibody VY7523 for Alzheimer's disease and the gene therapy candidate VY1706, alongside collaborations with Novartis and Neurocrine Biosciences.
Despite holding a sizable cash position and an analyst consensus of "Strong Buy," VYGR has experienced pronounced downward price pressure in recent weeks, with the stock trading well below its levels of a year ago and near the lower end of its recent range. Sentiment has been weighed down by concerns about the addressable patient population for certain programs, questions around brain-penetration efficiency, and the long development timelines inherent to central nervous system therapies. Recent quarterly results showed modest collaboration revenue and a continued net loss, though the company has indicated its cash position is expected to fund operations into 2028.
Trending AI Robots
For traders who prefer a data-driven approach, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron maintains hundreds of AI trading bots that monitor thousands of different tickers, but only a select group that is best suited to current market conditions earns a place in this trending section. These bots vary widely in trading style, strategy, timeframe, performance history, and the set of tickers they follow, allowing users to compare approaches ranging from short-term swing trading to longer-horizon trend following. Browsing the curated list can help investors see how algorithmic systems are interpreting momentum, volatility, and positioning across names like MGNX and VYGR. Explore the Trending AI Robots page to review the currently featured strategies.
Head-to-Head Comparison
The most immediate contrast between these two stocks is momentum. MGNX has demonstrated consistent relative strength, rising sharply over the trailing year and attracting upward price-target revisions, while VYGR has been in a sustained decline despite favorable analyst ratings. In terms of business model, MacroGenics benefits from recurring royalty and milestone income from partnered products such as ZYNYZ and TZIELD, giving it a more tangible near-term revenue stream. Voyager's revenue is almost entirely collaboration-based and remains minimal.
Risk profiles also differ. MacroGenics faces execution and clinical-safety risk around its ADC and bispecific programs but has recently reduced balance-sheet risk through asset monetization. Voyager carries higher platform and timeline risk, as its lead programs are earlier-stage and its market opportunity remains tied to unproven delivery technology. On valuation, VYGR trades with a higher implied upside relative to consensus targets, but that gap partly reflects weaker current market sentiment rather than confirmed fundamentals.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst positioning, Tickeron's AI would likely favor MGNX in the current environment. MacroGenics shows more consistent upward price momentum, improving balance-sheet stability, and a pipeline of near-term catalysts, whereas VYGR remains in a downtrend with sentiment still under pressure. That said, this assessment is probabilistic rather than definitive: both names carry substantial clinical-stage risk, and shifts in trial data or partnership news could alter relative positioning quickly. The AI's preference reflects current trend and stability signals, not a forecast of guaranteed outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGNX is a Hold and VYGR is a Buy.
MGNX's RSI Oscillator ascends from oversold territory
The RSI Oscillator for MGNX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 23 of the 26 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 50-day moving average for MGNX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.498). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VYGR in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 42 cases where VYGR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VYGR's RSI Indicator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 61 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +15.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VYGR as a result. In 82 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.744) is normal, around the industry mean (3.498). P/E Ratio (-1.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MGNX | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 47 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 87 | |
P/E GROWTH RATING 1..100 | 10 | 12 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VYGR's Valuation (47) in the Biotechnology industry is somewhat better than the same rating for MGNX (88). This means that VYGR’s stock grew somewhat faster than MGNX’s over the last 12 months.
VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGNX (100). This means that VYGR’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's SMR Rating (97) in the Biotechnology industry is in the same range as VYGR (98). This means that MGNX’s stock grew similarly to VYGR’s over the last 12 months.
MGNX's Price Growth Rating (65) in the Biotechnology industry is in the same range as VYGR (87). This means that MGNX’s stock grew similarly to VYGR’s over the last 12 months.
MGNX's P/E Growth Rating (10) in the Biotechnology industry is in the same range as VYGR (12). This means that MGNX’s stock grew similarly to VYGR’s over the last 12 months.
| MGNX | VYGR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 84% | 4 days ago 83% |
| Declines ODDS (%) | 8 days ago 84% | 2 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGNX’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- MGNX’s FA Score: 1 green, 4 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGNX’s TA Score shows that 5 TA indicator(s) are bullish while VYGR’s TA Score has 5 bullish TA indicator(s).
- MGNX’s TA Score: 5 bullish, 4 bearish.
- VYGR’s TA Score: 5 bullish, 3 bearish.
Price Growth
MGNX (@Biotechnology) experienced а +0.43% price change this week, while VYGR (@Biotechnology) price change was -5.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MGNX is expected to report earnings on Feb 25, 2027.
VYGR is expected to report earnings on Mar 09, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MGNX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | -4.13% | ||
| KRRO - MGNX | 45% Loosely correlated | -8.39% | ||
| AMRN - MGNX | 44% Loosely correlated | -0.34% | ||
| VYGR - MGNX | 42% Loosely correlated | -3.56% | ||
| ZVRA - MGNX | 39% Loosely correlated | -0.59% | ||
| MLTX - MGNX | 34% Loosely correlated | +7.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| WDNA | 23.57 | 0.09 | +0.39% |
| WisdomTree BioRevolution Fund (WDNA) | |||
| PVI | 24.88 | 0.04 | +0.14% |
| Invesco Floating Rate Municipal Income ETF (PVI) | |||
| NCIQ | 15.90 | N/A | N/A |
| Hashdex Nasdaq CME Crypto Index ETF | |||
| SMDX | 26.31 | N/A | N/A |
| Intech S&P Small-Mid Cap Diversified Alpha ETF | |||
| UITB | 45.22 | -0.03 | -0.08% |
| VictoryShares Core Intermediate Bond ETF (UITB) | |||